Eyeing Expansion Into Wealth Management, Vanguard Buys Fintech Altruist For As Much As $5 Billion

The acquisition is only the second ever for the 51-year-old company as it tries to expand beyond index-fund fees.

VCs Are So Obsessed With This AI Assistant That Its Valuation Jumped Fivefold In Weeks

A hot new AI agent called Instinct was valued at $500 million earlier in August, sources say. Now it’s raising a new round at a $2.5 billion valuation from Benchmark and Index.

A Silicon Valley Startup Aims To Fill A Battery Supply Chain Gap

This week’s Current Climate newsletter also looks at how DOGE broke America’s weather machine and using AI to create new materials for green hydrogen and batteries

Electric Copters Will Fly Out Of Downtown L.A. Ahead Of 2028 Olympics

Archer Aviation, which will test its eVTOLs over Los Angeles this year, plans a “vertiport” at AEG’s L.A. Live, next to the Lakers’ arena and city convention center.

3 Strategies Entrepreneurs Are Using To Scale Smarter With AI

AI can help a business do more without doing more of everything. The founders getting real value from it are using it to protect what makes their business worth building.

Josh Kushner’s Fortune Tripled This Year Thanks To Stakes In OpenAI, SpaceX And More

The Kushner scion’s VC firm Thrive Capital nearly tripled its assets thanks to smart bets on OpenAI and SpaceX. Now he’s looking to spend some cash on the NBA’s Lakers.

Fall Is The Best Time To Visit These 12 U.S. National Parks

Whether you’re chasing fall colors or fewer crowds, these national parks offer some of the best autumn travel experiences in the country.

This Billionaire Is Using AI To Forecast Evolutionary Change

AI’s big debt load. Moving backward on defense tech. Why we need to talk about CPUs. All that and more in this week’s Prototype.

TikTok Profits Off Drug Dealer Ads For Cocaine, Opioids And Xanax

The Chinese-owned social network has been flooded with advertisements pushing street drugs and prescription pills like codeine, benzos and Adderall.

Italy’s $10 Billion Pharma Family Makes A U.S. Power Move

For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market.